The risk for developing a second primary tumor in long surviving cancer patients

Chirilă Monica-Emilia, Fekete Zsolt

Oncology Institute,
Cluj-Napoca, Romania

Nothing to declare
Introduction

• Survival rate in cancer patients has increased in recent years and it is still growing. In these patients, there is a significant risk for developing a second primary tumor because of risk factors like genetic background, unhealthy behaviors or side effects from the therapy of the first cancer.

• The goal of this study was to evaluate the incidence of different types of malignancies in readmitted long-term cancer survivors.

• An additional goal was to assess the risk of developing a metachronous tumor in patients with long-term survival.
Results I

2014-2015 inpatients of Radiation Oncology Department Cluj-Napoca

Long-term survivors - First cancer site

- History less than 5 years: 110
- No sign of disease: 44
- Progression: 20
- Relapse: 21
- Metachronous tumors: 25

- Man:
  - Head and neck: 23%
  - Lung: 14.60%
  - Urinary bladder: 6.30%

- Woman:
  - Head and neck: 6.70%
  - Lung: 3.30%
  - Urinary bladder: 0%
Results II

The number of patients who developed a metachronous tumor according to the most frequent first cancer sites

- **Head and neck**: Previously diagnosed - 11, Developed a second cancer - 5
- **Lung**: Previously diagnosed - 7, Developed a second cancer - 2
- **Nervous system**: Previously diagnosed - 5, Developed a second cancer - 0
- **Prostate**: Previously diagnosed - 8, Developed a second cancer - 2

- **Breast**: Previously diagnosed - 14, Developed a second cancer - 12
- **Cervix**: Previously diagnosed - 8, Developed a second cancer - 4
- **Endometrium**: Previously diagnosed - 7, Developed a second cancer - 3
- **Ovary**: Previously diagnosed - 6, Developed a second cancer - 1
Conclusions

Metachronous cancers are a frequent cause of readmission of patients with survival greater than 5 years.

Smoke related cancers (head and neck, lung) and less aggressive tumors (breast, prostate) represent a higher risk.

Pro-active follow-up could detect early stage second primary cancer in these categories.